Anti-Inhibitor Coagulant Complex

Summary

Anti-Inhibitor Coagulant Complex (CHEMBL4297953) is a phase-3 clinical-stage unknown; indicated across 4 conditions including hemophilia a and hemophilia b.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297953
Name	Anti-Inhibitor Coagulant Complex
Type	Unknown
Max phase	3

Also known as: Anti inhibitor coagulant complex, Anti-inhibitor coagulant complex, Antiinhibitor coagulant complex, Factor viii bypassing fraction, Factor viii inhibitor bypassing fraction, Feiba, ANTI-INHIBITOR COAGULANT COMPLEX

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hemophilia A	3	MONDO:0010602	MONDO:0010602
hemophilia B	3	MONDO:0010604	MONDO:0010604
heart disorder	2	MONDO:0005267	EFO:0003777
cardiovascular disorder	1	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2
PHASE4	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04205175	PHASE4	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab
NCT04563520	PHASE3	RECRUITING	SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
NCT02764489	PHASE3	COMPLETED	FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)
NCT07032792	PHASE2	RECRUITING	Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery
NCT05020483	PHASE2	WITHDRAWN	FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients
NCT02577614	PHASE1	COMPLETED	FEIBA and Use of Blood Products in Cardiac Surgery
NCT00166309	Not specified	COMPLETED	The FEIBA NovoSeven Comparative Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).